Breaking News Headlines Today | Ground News

See every side of every news story

pharmatimes.com image

News from pharmatimes.com

pharmatimes.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is pharmatimes.com credible or reliable? Our Factuality score answers both of those questions. When it comes to pharmatimes.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about pharmatimes.com

Where is pharmatimes.com located?pharmatimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmatimes.com News

Cancer Research UK Partners with Nxera on Next-Stage Trial for HTL0039732

London, England · London

Cancer Research UK Partners with Nxera on Next-Stage Trial for HTL0039732

100% Center coverage: 1 sources

The Phase IIa study will test HTL0039732 in combination with immunotherapy to boost responses in resistant solid tumors and broaden treatment choices.See the Story

Imfinzi becomes first NHS drug for aggressive lung cancer

NHS · United Kingdom

Imfinzi becomes first NHS drug for aggressive lung cancer

100% Center coverage: 1 sources

AstraZeneca's PD-L1 inhibitor Imfinzi is the first drug therapy to be recommended for routine NHS use in limited-stage small cell lung cancer See the Story

Three-Year Data Reinforce Long-Term Efficacy and Safety of Bimekizumab in Hidradenitis Suppurativa

Three-Year Data Reinforce Long-Term Efficacy and Safety of Bimekizumab in Hidradenitis Suppurativa

At EADV 2025, UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.See the Story

Breaking News Topics Related to pharmatimes.com